Articles tagged "Rejection"

2016 American Transplant Congress
Everolimus in Combination with Reduced Dose Tacrolimus Is Effective as a Prophylaxis of Acute Rejection in Low-to-Moderate Immunologic Risk De Novo Kidney Transplantation Patients.
Y. Qazi, F. Shihab, S. Mulgaonkar, K. MaCague, D. Patel.
University of Southern California, Los Angeles; University of Utah, Salt Lake City; Barnabas Health, West Orange; Novartis Pharmaceuticals Corporation, East Hanover.
The US92 study determined whether, in de novo renal transplant patients (pts), concentration-controlled everolimus (EVR) with reduced dose tacrolimus (RTAC) is non-inferior compared to CellCept®…
2016 American Transplant Congress
Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
X. Wen,¹ M. Casey,¹ A. Santos,¹ A. Hartzema,² K. Womer.¹
¹Department of Medicine, University of Florida, Gainesville, FL; ²Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL.
To examine the utilization and clinical outcomes of belatacept in the real clinical setting, a retrospective cohort study was conducted using SRTR data that compared…
2016 American Transplant Congress
Malignancies Contribute to Presensitization with Alloreactive T-Cells in Kidney Transplant Recipients.
T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
¹Nephrology and Internal Intensive Care, Charite Campus Virchow Clinic, Berlin, Germany; ²Berlin-Brandenburg Center for Regenerative Therapies, Charite Campus Virchow Clinic, Berlin, Germany.
Alloreactive T-cells have been suggested to impact allograft outcome due to a higher incidence of acute rejection in the initial period after kidney transplantation. Knowledge…
2016 American Transplant Congress
Interaction Between Kidney Tissue Proteome and Humoral Immunity in Antibody Mediated Rejection.
A. Konvalinka,¹ A. Chruscinski,² S. Kim,¹ K. Tinckam,¹ I. Jurisica,³ R. John.⁴
¹Medicine/Division of Nephrology, Toronto General Hospital, Toronto, ON, Canada; ²Medicine/Division of Cardiology, Toronto General Hospital, Toronto, ON, Canada; ³Medical Biophysics and Computational Science, University of Toronto, Toronto, ON, Canada; ⁴Pathology, Toronto General Hospital, Toronto, ON, Canada.
PURPOSE: Antibody-mediated rejection (AMR) is caused by antibodies against human leukocyte antigens (HLA) on graft endothelium, and non-HLA antibodies that target endothelial and epithelial proteins.…
2016 American Transplant Congress
Rapid Emergence of CD28^null Cells Following Ex Vivo Restimulation Is Associated with Belatacept Resistant Rejection.
M. Cortes, S. Laurie, B. Sayed, M. Ford.
Emory Transplant Center, Atlanta, GA.
Numerous studies have implicated donor-reactive memory T cells in mediating costimulation blockade resistant rejection (CoBRR) following treatment with belatacept. In humans, these memory T cells…
2016 American Transplant Congress
Plasma Endothelial Microvesicle Counts Indicate Allograft Rejection Following Kidney Transplantation.
D. Zecher,¹ A. Cumpelik,² B. Ruhland,¹ B. Banas,¹ H. Hopfer,³ M. Dickenmann,⁴ J. Schifferli.²
¹Nephrology, Regensburg University Hospital, Regensburg, Germany; ²Biomedicine, Basel University Hospital, Basel, Switzerland; ³Pathology, Basel University Hospital, Basel, Switzerland; ⁴Nephrology, Basel University Hospital, Basel, Switzerland.
Background: The release of surface-derived microvesicles (MV) is a common phenomenon of cellular activation and occurs specifically as a consequence of terminal complement complex assembly…
2016 American Transplant Congress
Quadruple Induction Regimen with Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Improves Graft Function without Increase in the Incidence of Microvascular Inflammation or De Novo Donor Specific Antibody Compared to the Standard Triple Regimen.
M. Miura, H. Higashiyama.
Department of Urology and Renal Transplantation Surgery, Sapporo Hokuyu Hospital, Sapporo, Japan.
Objectives: Nephrotoxicity of calcineurin inhibitors (CNI) in kidney allografts has been a significant problem even with low exposure regimens. On the other hand, CNI-free regimen…
2016 American Transplant Congress
Postoperative Rebound of Anti-Blood Type Antibodies and Antibody-Mediated Rejection After ABO-Incompatible Living Related Kidney Transplantation – Is Prophylactic Treatment Necessary?
H. Ishida, T. Kondo, T. Shimizu, T. Nozaki, K. Tanabe.
Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
PURPOSE: The role of postoperative anti-ABO titers in acute rejection under our current immunosuppressive regimen remains unclear. Some institutions recommend postoperative therapeutic plasma exchange to…
2016 American Transplant Congress
Association of Genetic Polymorphisms in Complement Independent Pathways with Donor Specific Antibodies in Kidney Allograft Recipients.
Y. Chang,^1,2 T. Shah,^1,3 D. Min.¹
¹Western University of Health Sciences, Pomona, CA; ²Mendez National Institute of Transplantation Foundation, Los Angeles, CA; ³St. Vincent Medical Center, Los Angeles, CA.
Background: It is known that detection of donor specific antibodies (DSA) is associated with antibody mediated rejection (AMR) and poor allograft outcomes. DSA mediates graft…
2016 American Transplant Congress
Focal C4d Staining in Biopsies of Kidney Transplant Recipients Is Not Associated with Antibody Mediated Rejection and Does Not Correlate with Graft Survival.
R. Prashar, M. Goggins, L. Yessayan, A. Patel, M. Goggins.
Transplant Institute, Henry Ford Hospital, Detroit, MI.
Introduction: While diffuse C4d positivity in kidney transplant peritubular capillaries(PTC) strongly co-relates with the presence of antibody mediated rejection(AMR),data on the significance of focal C4d…